Category: 3. Business

Kellanova (K) stock has been catching some attention lately, as investors look beyond day-to-day moves to assess its strategic direction and broader performance. With steady revenue and net income growth reported, the company is maintaining momentum in a competitive market.

See our latest analysis for Kellanova.

Kellanova’s share price has climbed 5.2% in the past three months, reflecting renewed optimism as the company continues to post steady results amid industry competition. With a 5.8% total shareholder return over the past year and a cumulative five-year total return of 68.3%, momentum appears to be building as investors focus on its long-term story.

If you’re on the lookout for what else might offer solid upside, now could be a great time to broaden your search and discover fast growing stocks with high insider ownership

With the stock posting consistent gains yet trading right around analyst targets, the big question now is whether Kellanova is undervalued with room to run, or if the market is already pricing in its future growth.

With Kellanova’s share price closing at $83.64 and the widely followed narrative fair value target set at $83.39, investors are seeing a close alignment between current market sentiment and projected earnings potential. This minimal difference signals that the latest company outlook is largely priced in, but it is worth examining what is driving this consensus.

The company’s focus on differentiated geographic footprint, particularly in emerging markets, should lead to sequential volume improvement and organic growth in net sales, positively impacting revenue. A heavy calendar of innovation, including product launches in snacks and away-from-home channels, is projected to increase net sales contribution from innovation, driving revenue growth.

Read the complete narrative.

Curious what kind of earnings growth and profit margins are backing this fair value? The narrative relies on a blueprint of aggressive innovation, bold new launches, and ambitious performance metrics. Want to see which numbers the valuation hinges on? Uncover the details that the market is watching closely.

Result: Fair Value of $83.39 (ABOUT RIGHT)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, shifts in consumer spending in Europe or innovation setbacks in major product launches could challenge Kellanova’s steady growth outlook.

Find out about the key risks to this Kellanova narrative.

While the consensus price target suggests Kellanova is fairly valued, our DCF model estimates the company’s fair value at $95.81. This is 12.7% above the current share price. This method implies the market might be overlooking potential upside. Could the real value be higher than expected?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Kellanova for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 920 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

If you think the story could unfold differently or want to review the numbers firsthand, you can craft your own perspective in just minutes. Do it your way

A great starting point for your Kellanova research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Don’t let opportunity slip away. Expand your horizons now and take advantage of exclusive stock ideas the market hasn’t fully noticed yet with the Simply Wall Street Screener.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include K.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Story Continues

Investors are often guided by the idea of discovering ‘the next big thing’, even if that means buying ‘story stocks’ without any revenue, let alone profit. But as Peter Lynch said in One Up On Wall Street, ‘Long shots almost never pay off.’ A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.

If this kind of company isn’t your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Xylem (NYSE:XYL). Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

The market is a voting machine in the short term, but a weighing machine in the long term, so you’d expect share price to follow earnings per share (EPS) outcomes eventually. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. It certainly is nice to see that Xylem has managed to grow EPS by 30% per year over three years. As a general rule, we’d say that if a company can keep up that sort of growth, shareholders will be beaming.

One way to double-check a company’s growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. While we note Xylem achieved similar EBIT margins to last year, revenue grew by a solid 5.6% to US$8.9b. That’s encouraging news for the company!

You can take a look at the company’s revenue and earnings growth trend, in the chart below. Click on the chart to see the exact numbers.

View our latest analysis for Xylem

The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don’t exist, you can check our visualization of consensus analyst forecasts for Xylem’s future EPS 100% free.

We would not expect to see insiders owning a large percentage of a US$34b company like Xylem. But we are reassured by the fact they have invested in the company. We note that their impressive stake in the company is worth US$194m. This comes in at 0.6% of shares in the company, which is a fair amount of a business of this size. This still shows shareholders there is a degree of alignment between management and themselves.

While it’s always good to see some strong conviction in the company from insiders through heavy investment, it’s also important for shareholders to ask if management compensation policies are reasonable. Well, based on the CEO pay, you’d argue that they are indeed. Our analysis has discovered that the median total compensation for the CEOs of companies like Xylem, with market caps over US$8.0b, is about US$13m.

The Xylem CEO received US$11m in compensation for the year ending December 2024. That is actually below the median for CEO’s of similarly sized companies. CEO compensation is hardly the most important aspect of a company to consider, but when it’s reasonable, that gives a little more confidence that leadership are looking out for shareholder interests. It can also be a sign of good governance, more generally.

If you believe that share price follows earnings per share you should definitely be delving further into Xylem’s strong EPS growth. If you still have your doubts, remember too that company insiders have a considerable investment aligning themselves with the shareholders and CEO pay is quite modest compared to similarly sized companiess. Everyone has their own preferences when it comes to investing but it definitely makes Xylem look rather interesting indeed. It is worth noting though that we have found 1 warning sign for Xylem that you need to take into consideration.

Although Xylem certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with more skin in the game, then check out this handpicked selection of companies that not only boast of strong growth but have strong insider backing.

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

• Wondering if Eni’s recent run puts the stock at a discount or if the best value days are already behind it? You’re not alone, as investors everywhere are asking the same question right now.

• Eni’s share price has climbed 19.8% so far this year and 29.1% over the past 12 months, indicating renewed optimism and possible growth ahead.

• Much of this excitement has been fueled by recent positive developments in the energy sector, including moves toward cleaner production and new international projects. News highlighting Eni’s investment in low-carbon initiatives and overseas exploration has caught investors’ attention and contributed to the stock’s upward momentum.

• On the valuation front, Eni scores a 3 out of 6 based on our undervaluation checks. Next, we will explore the methods behind that score and provide insights to help better understand Eni’s real value.

Eni delivered 29.1% returns over the last year. See how this stacks up to the rest of the Oil and Gas industry.

The Discounted Cash Flow (DCF) model estimates a company’s value by projecting its future cash flows and discounting them back to today’s value. This approach helps investors gauge the present worth of all expected future cash the business will generate, using current financial data and reasonable growth assumptions.

For Eni, the most recent Free Cash Flow stands at approximately €4.40 billion. According to analyst consensus and Simply Wall St extrapolations, these cash flows are forecast to grow moderately, with projections reaching roughly €5.19 billion by 2028 and continuing upwards through 2035. Early estimates rely on analyst forecasts, while later years use logical estimates based on prevailing growth trends in the sector.

Using these inputs, the DCF analysis values Eni at an intrinsic fair value of €22.02 per share. This suggests that the current market price is about 26.7 percent below what the company’s future cash flows are worth today, indicating the stock is significantly undervalued according to this model. For investors seeking growth and value, this assessment may indicate a promising entry point.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Eni is undervalued by 26.7%. Track this in your watchlist or portfolio, or discover 920 more undervalued stocks based on cash flows.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Eni.

The Price-to-Earnings (PE) ratio is a well-known method used to value profitable companies like Eni, as it connects the market price to the company’s actual earnings. This metric is especially relevant for established businesses with positive earnings, offering a straightforward way to compare value across the sector.

It’s important to remember that what counts as a “normal” or “fair” PE ratio can change depending on growth prospects and perceived risk. Companies expected to grow rapidly or those considered safer investments typically command higher PE ratios, while riskier or slower-growing firms usually see lower multiples.

Currently, Eni trades at a PE ratio of 18.7x, which is higher than both the industry average of 13.3x and the peer group average of 13.1x. At first glance, this might suggest Eni is more expensive than its rivals. However, simply comparing these averages does not tell the whole story. This is where Simply Wall St’s “Fair Ratio” comes in. The Fair Ratio, calculated at 21.5x for Eni, incorporates not just earnings but also factors like Eni’s growth outlook, profitability, risk profile, industry position, and its size in the market.

The Fair Ratio is a more holistic metric than industry or peer comparisons because it is tuned to Eni’s specific fundamentals, rather than being based on broader or less relevant companies. In this case, Eni’s actual PE ratio is about 2.8x below its Fair Ratio, indicating that, on this measure, the stock could be considered undervalued.

Result: UNDERVALUED

PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1443 companies where insiders are betting big on explosive growth.

Earlier we mentioned that there is an even better way to understand valuation, so let’s introduce you to Narratives. A Narrative is your own story about a company that connects what you believe about its business, industry changes, and trends with the actual numbers, such as fair value, future revenue, earnings, and profit margins.

Rather than simply relying on historic data or a single metric, Narratives let you link what is happening in the real world to a financial forecast and, ultimately, to what you believe is a fair price for the stock. This approach is accessible and easy to use for investors of all experience levels on Simply Wall St, right from the Community page used by millions.

Narratives empower you to decide when to buy or sell, making it simple to see at a glance how your fair value compares to the current price. Because they update automatically with new information, such as news, earnings reports, or industry developments, your view is always relevant and up to date.

For example, when it comes to Eni, some investors are optimistic and see a fair value as high as €17.5, while others, more cautious, estimate just €13.5. This illustrates how Narratives capture the range of real investor perspectives and make stock decisions more intuitive and personal.

Do you think there’s more to the story for Eni? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ENI.MI.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Story Continues

Story Continues

Story Continues

Welcome to OncLive®’s OncFive!

Every week, we bring you a quick roundup of the 5 top stories from the world of oncology—ranging from pivotal regulatory decisions to key pipeline updates to expert insights on breakthroughs that are moving the needle in cancer care. This resource is designed to keep you informed on the latest updates in the space, in just a matter of minutes.

Here’s what you may have missed this week:

The FDA approved durvalumab (Imfinzi) for use in combination with FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) as neoadjuvant and adjuvant treatment, followed by single-agent durvalumab, for adult patients with resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma.¹

The regulatory decision was supported by findings from the phase 3 MATTERHORN trial (NCT04592913), which showed durvalumab plus FLOT reduced the risk of disease progression, recurrence, or death by 29% compared with FLOT alone; The median event-free survival (EFS) was not reached (95% CI, 40.7-not estimable [NE]) with durvalumab vs 32.8 months (95% CI, 27.9-NE) with FLOT alone. (HR, 0.71; 95% CI, 0.58-0.86; P < .001). The pathological complete response rate was 19.2% (95% CI, 15.7%-23.0%) in the durvalumab arm vs 7.2% (95% CI, 5.0%-9.9%) in the FLOT alone arm (P < .001).

The FDA has granted priority review to a new drug application (NDA) seeking the approval of sonrotoclax (BGB-11417) for the treatment of adult patients with relapsed or refractory MCL who have received prior treatment with a BTK inhibitor.²

The NDA is supported by findings from the phase 1/2 BGB-11417-201 trial (NCT05471843), which met its primary end point of overall response rate (ORR) per independent review committee (IRC) and showed clinically meaningful responses among 125 adult patients with relapsed/refractory disease previously treated with a BTK inhibitor. Full data from the study that support the NDA will be presented at the 2025 ASH Annual Meeting.

Treatment with Sacituzumab tirumotecan (sac-TMT; SKB264/MK-2870) in combination with pembrolizumab (Keytruda) yielded a statistically significant and clinically meaningful improvement in progression-free survival (PFS) vs pembrolizumab alone in patients with PD-L1–positive advanced non–small cell lung cancer (NSCLC), meeting the primary end point of the phase 3 OptiTROP-Lung05 trial (NCT06448312).³

Overall survival also trended in favor of the sac-TMT regimen, per independent data monitoring committee assessment. Based on these findings, an NDA could be submitted to the Center for Drug Evaluation of the National Medical Products Administration in China seeking the approval of sac-TMT in this indication.

Treatment with subcutaneous toripalimab (JS001sc) in combination with chemotherapy generated comparable pharmacokinetics (PK) compared with intravenous (IV) toripalimab (Loqtorzi) plus chemotherapy in patients with recurrent or metastatic nonsquamous non–small cell lung cancer (NSCLC), meeting the primary end points of the phase 3 JS001sc-002-III-NSCLC trial (NCT06505837).⁴

The study met both its primary end points: observed serum C_trough concentration at cycle 1 and model-predicted area under the concentration time curve from 0 to 21 days at cycle 1. Findings also demonstrated that subcutaneous toripalimab produced comparable efficacy and safety outcomes compared with the IV formulation. Full trial data will be presented at an upcoming international medical conference.

The European Commission approved lisocabtagene maraleucel (Breyanzi; liso-cel) for the treatment of adult patients with relapsed or refractory MCL following at least 2 prior lines of systemic therapy, including a BTK inhibitor.⁵

This regulatory decision is supported by data from the MCL cohort of the phase 1 TRANSCEND NHL 001 trial (NCT02631044), which showed that liso-cel generated an ORR of 82.7% (95% CI, 72.7%-90.2%) and a complete response rate of 71.6% (95% CI, 60.5%-81.1%). The median time to first response was 0.95 months, and 41.2% (95% CI, 29.2%-52.9%) of patients remained in response at 24 months.

References

1. FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma. FDA. November 25, 2025. Accessed November 26, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-resectable-gastric-or-gastroesophageal-junction-adenocarcinoma
2. U.S. FDA grants priority review to sonrotoclax for the treatment of relapsed or refractory mantle cell lymphoma. News release. BeOne Medicines. November 26, 2025. Accessed November 26, 2025. https://ir.beonemedicines.com/news/us-fda-grants-priority-review-to-sonrotoclax-for-the-treatment-of-relapsed-or-refractory-mantle/786f1dad-0c9f-492e-9fce-f9ceadd24989
3. Kelun-Biotech announces phase 3 trial of sac-TMT in combination with Keytruda (pembrolizumab) as first-line treatment for PD-L1–positive NSCLC met primary endpoint. News Release. PR Newswire. November 24, 2025. Accessed November 26, 2025. https://www.prnewswire.com/news-releases/kelun-biotech-announces-phase-iii-trial-of-sac-tmt-in-combination-with-keytruda-pembrolizumab-as-first-line-treatment-for-pd-l1-positive-nsclc-met-primary-endpoint-302624279.html
4. Junshi Biosciences announces primary endpoints met in JS001sc’s phase 3 study for the 1st-line treatment of NSQ-NSCLC. News release. Shanghai Junshi Biosciences. November 24, 2025. Accessed November 26, 2025. https://www.globenewswire.com/news-release/2025/11/25/3193998/0/en/Junshi-Biosciences-Announces-Primary-Endpoints-Met-in-JS001sc-s-Phase-3-Study-for-the-1ST-line-Treatment-of-NSQ-NSCLC.html
5. Bristol Myers Squibb receives approval from the European Commission to expand use of CAR T cell therapy Breyanzi for relapsed or refractory mantle cell lymphoma. News release. Bristol Meyers Squibb. November 24, 2025. Accessed November 26, 2025. https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Receives-Approval-from-the-European-Commission-to-Expand-Use-of-CAR-T-Cell-Therapy-Breyanzi-for-Relapsed-or-Refractory-Mantle-Cell-Lymphoma/default.aspx